Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PEP-CMV by Immunomic Therapeutics for Anaplastic Astrocytoma: Likelihood of Approval
PEP-CMV is under clinical development by Immunomic Therapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...